{"id":248,"date":"2026-04-25T10:09:15","date_gmt":"2026-04-25T10:09:15","guid":{"rendered":"https:\/\/consult.genixfertilitycare.com\/index.php\/2026\/04\/25\/utm_campaignrss\/"},"modified":"2026-04-25T10:09:15","modified_gmt":"2026-04-25T10:09:15","slug":"utm_campaignrss","status":"publish","type":"post","link":"https:\/\/consult.genixfertilitycare.com\/index.php\/2026\/04\/25\/utm_campaignrss\/","title":{"rendered":"FDA fast-tracks review of new psychedelic mental health treatments"},"content":{"rendered":"


\n
<\/p>\n

\n

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT\u2019s industry-leading events.<\/p>\n<\/div>\n

\n

The Food and Drug Administration will accelerate its review of psychedelic drugs developed by Compass Pathways, the Usona Institute, and Transcend Therapeutics for mental health disorders, as part of the Trump administration\u2019s plan to boost access to the controversial yet promising medications.<\/p>\n

The agency will grant priority review vouchers specifically to Compass\u2019 psilocybin product for treatment-resistant depression, Usona\u2019s similar medicine for major depressive disorder, and an MDMA-like treatment for post-traumatic stress disorder from Transcend.\u00a0<\/p>\n

The FDA identified the medications receiving the vouchers, but not the companies developing them. Compass, Usona, and Transcend confirmed they received vouchers.<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\n\t\t\t\t
\n\t\t\t\t\t<\/p>\n

\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t